Study to Investigate the Efficacy and Safety of QGE031 in Adolescent Patients With Chronic Spontaneous Urticaria (CSU)

NCT03437278 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

49

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Spontaneous Urticaria

Interventions

DRUG: Ligelizumab
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals